Suven Life Sciences Gets Patents From India, New Zealand
Suven said that the patents are valid until 2024 and 2025 respectively. The granted claims of the patents include the class of selective 5-HT compounds discovered by the
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
The second Phase I/II trial was a randomised, single-blind, placebo-controlled, escalating double-dose safety study conducted at the Sourasky Medical Center in Tel Aviv, Israel, in which a total